Major histocompatibility complex class II presenting Wilms tumor 1-derived peptides (MHC II-WT1)

The Major Histocompatibility Complex (MHC) class II presenting Wilms tumor 1 (WT1)-derived peptides is a critical immunological target in oncology. WT1 is a transcription factor that is highly overexpressed in various hematological malignancies, such as acute myeloid leukemia (AML), and several solid tumors, while maintaining limited expression in normal adult tissues (Source: PubMed, PMID: 17409431). When WT1-derived peptides are processed and presented by MHC class II molecules on the surface of antigen-presenting cells or tumor cells, they are recognized by the T-cell receptors (TCRs) of CD4+ T helper cells (Source: PubMed, PMID: 25139351). This interaction is essential for orchestrating a robust and sustained anti-tumor immune response, as CD4+ T cells provide necessary help for the activation and memory formation of CD8+ cytotoxic T cells (Source: PubMed, PMID: 22431868). Therapeutic strategies targeting this complex include peptide vaccines, such as Galinpepimut-S, and adoptive cell therapies using TCR-engineered T cells (Source: SELLAS Life Sciences). By specifically targeting the WT1-MHC II complex, these therapies aim to selectively eliminate malignant cells while minimizing damage to healthy tissues.

Other names

HLA class II-WT1 peptide complexWT1-MHC II complexWilms tumor 1-MHC class II complexWT1-HLA-DR complex

Presentation of tumor-associated WT1 peptides to CD4+ T-cell receptors to induce a helper T-cell response and enhance overall anti-tumor immunity.